IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates

Go back to IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates
(NASDAQ: ICCM) Delayed: 5.93 +0.53 (9.81%)
Previous Close $5.40    52 Week High
Open $7.06    52 Week Low
Day High $7.53    P/E N/A 
Day Low $5.61    EPS
Volume 15,898,920